- About Us
- Investor Relations
Isa Odidi, Ph.D., MBAChairman, CEO, CSO
In 1998, Dr. Odidi co-founded Intellipharmaceutics Inc., the predecessor of publicly-traded Intellipharmaceutics International Inc. From 1995 to 1998, Dr. Odidi held positions, first as Director, then as Vice President of Research of Drug Development and New Technologies, at Biovail Corporation International, (now Valeant Pharmaceutical International, Inc.), a drug delivery company.
Prior to 1995, Dr. Odidi held several senior positions in academia and in the pharmaceutical and health care industries. His work has been cited in textbooks and he has published over a hundred scientific and medical papers, articles, and textbooks.
He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine in California.
Dr. Odidi received his B.Sc. Pharmacy (Ahmadu Bello University, Nigeria), M.Sc. Pharmaceutical Technology, Ph.D. Pharmaceutics (University of London), and MBA (Joseph L. Rotman School of Management, University of Toronto), is also a graduate of the Western Executive Program, Ivey School of Business (University of Western Ontario). Dr. Odidi recently awarded Honorary Doctor of Science degree (Honoris causa) University of Benin, Nigeria.
Amina Odidi , Ph.D.President, COO, CSO
In 1998, Dr. Amina Odidi co-founded Intellipharmaceutics Inc., the predecessor of publicly-traded Intellipharmaceutics International Inc. She has been President, COO, and Co-Chief Scientist since 1998. Dr. Amina Odidi has extensive experience developing and applying proprietary technologies to the development of controlled-release drug products for third-party pharmaceutical companies. She has invented or co-invented various proprietary controlled delivery devices for the delivery of pharmaceutical, nutriceutical, biological, agricultural and chemical agents. Previously she has worked for the pharmaceutical and health care industry. She has co-authored 8 articles, papers and textbooks. She received her B.Sc. in Pharmacy, M.S. in Biopharmaceutics, and her Ph.D. in Pharmaceutics from the University of London.
Domenic Della PennaChief Financial Officer, CPA, CA, MBA
Mr. Della Penna joined Intellipharmaceutics in November, 2014. Mr. Della Penna brings considerable expertise and industry experience to the company, having held senior posts at several industry leading multinationals. He had previously served as CFO of Teva Canada Limited since December 2010, and he simultaneously served as Interim CFO of Teva North America Generics in the United States since December 2013. His responsibilities and accomplishments in those roles included enhancements to strategic planning processes and financial systems, integration of assets acquired in the purchase of ratiopharm Canada by Teva, business development, and the negotiation of in-licensing opportunities, mergers and acquisitions. Prior to his time at Teva, Mr. Della Penna was the CFO of Timothy's Coffees of the World, Vice President of Finance of Diageo Canada Inc., and Vice President of Finance Nestle Canada Inc. (Ice Cream division). In all these roles Mr. Della Penna made significant contributions to various mergers, acquisitions, divestitures and organizational change mandates.
Mr. Della Penna is a Chartered Accountant (C.A.), a Chartered Professional Accountant (CPA), and holds a Master of Business Administration (MBA) degree from the Schulich School of Business at York University (Toronto).
Michael CampbellGeneral Counsel & Corporate Secretary, B.A. (Honours), LL.B
Mr. Campbell joined Intellipharmaceutics in July 2017. A solution-oriented executive and legal advisor, Mr. Campbell’s specialties include corporate finance, M&A, commercial operations, corporate development and business strategy. Since 2007, Mr. Campbell has been involved in the management of early stage companies at Griffis Capital, an incubator of businesses in the natural resources, information technology and healthcare industries. Prior to joining Griffis Capital, Mr. Campbell was a partner at McMillan LLP, a leading Canadian law firm. He has also served as General Counsel at Canada Cartage System, Canada’s largest private dedicated fleet transportation and logistics provider. Mr. Campbell holds a B.A. (Honours) from McGill University (Montreal, Quebec) and a law degree from Queen’s University (Kingston, Ontario).
Patrick N. Yat, Ph.D.Vice President, Chemistry & Analytical Services
Dr. Yat has been has been Vice President at Intellipharmaceutics since 2005 and has been involved in the pharmaceutical or pharmaceutical related industry since 1992 when he worked at Health Canada as Visiting Scientist. Previously, he worked at Patheon Inc., where he was instrumental in the successful take off of its pre-formulation unit. He also served with Biovail Corporation where he was involved in methods development and validation of the company's pipeline products as well as heading the pre-formulation activity for the company. Dr. Yat currently sits as an expert committee member of the USP on methods development and is on the advisory board of the Toronto Institute of Pharmaceutical Technology on QC program. Dr. Yat received his Ph.D. from the University of Salford, U.K. His Ph.D. research on Opioid analgesics was supported by industry.
Christian AkyemponVice President, Commercial Operations
Christian Akyempon is currently the Vice President, Commercial Operations, at Intellipharmaceutics Corp. In this role, Christian will oversee the strategic functions of Marketing, Sales and Business Development. Prior to assuming this role, Christian worked as the VP, Business Development for Global Pharma Partners with responsibilities for the Canadian market. Before then, he was the Director of Business Development and Government Affairs at Taro Canada until May 2013. Christian's extensive career with both generic and brand pharmaceutical firms include several managerial roles in Business Development, Marketing and Sales at Teva Canada, ratiopharm, GlaxoSmithKline and Sterling Winthrop. At Teva, Christian played a pivotal role in the integration of ratiopharm into Teva Canada. Over a 7-year period, Christian also provided strategic business solutions and market audits to pharma firms specializing in Diagnostic Imaging in the hospital environment through Medimark Consultants.
Christian holds an MBA degree from the University of Ottawa (ON), M.Sc. in Pharmaceutical Sciences from the University of British Columbia (BC), and an Honours B.Sc. from the University of Waterloo (ON).
- Press Releases
- Events & Presentations
- Media Articles
- Corporate Governance >
- Financial Information >
- Proxy Material
- Stock Information >
- Analyst Coverage
- Contact Us